Sub Banner Image

Nvidia, Palantir, Ionq, Novavax, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Benzinga Neuro

·

January 8, 2025

·

Benzinga

The U.S. stock market experienced a downturn on Tuesday, with the Nasdaq Composite falling by 1.9% and the S&P 500 dropping by 1.1%. The Dow Jones Industrial Average also declined by 0.4%.

These are the top stocks that gained the attention of retail traders and investors throughout the day:

Nvidia Corporation (NASDAQ:NVDA)

Nvidia’s stock dropped by 6.22%, closing at $140.14. The stock reached an intraday high of $153.13 and a low of $140.01, with a 52-week high of $153.13. During the CES 2025 keynote, CEO Jensen Huang unveiled the RTX 5000 series GPUs, capturing significant market interest.

Palantir Technologies Inc. (NYSE:PLTR)

Palantir’s shares fell by 7.81%, closing at $69.99. The day’s high was $75.39, with a low of $69.75, and a 52-week high of $75.39. Cathie Wood’s Ark Invest sold $15 million worth of Palantir shares on Monday and continued selling shares on Tuesday, reflecting mixed analyst ratings.

IonQ Inc. (NYSE:IONQ)

IonQ’s stock decreased by 2.90%, closing at $49.59. The stock hit a high of $54.74 and a low of $48.73, with a 52-week high of $54.74. The company announced the acquisition of Qubitekk, enhancing its quantum computing capabilities.

Moderna Inc. (NASDAQ:MRNA)

Moderna shares surged by 11.65%, closing at $47.53. The stock’s intraday high was $48.92, with a low of $42.86, and a 52-week high of $170.47. The rise follows reports of the first U.S. human bird flu death, boosting vaccine stocks.

Tesla Inc. (NASDAQ:TSLA)

Tesla’s stock fell by 4.06%, closing at $394.36. The stock’s high was $414.33, with a low of $390, and a 52-week high of $488.54. Despite a recent downgrade by Bank of America, investors remain focused on long-term prospects like FSD and robotaxis.

Image via Shutterstock

Prepare for the day’s trading with top premarket movers and news by Benzinga.

Read Next:

This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

More from

Benzinga

More

News

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.